Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …

In Parkinson disease (PD), pathological processes and neurodegeneration begin long
before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal …

Parkinson's disease is characterized by the presence of abnormal, intraneuronal α-
synuclein aggregates, which may propagate from cell-to-cell in a prion-like manner …

Endogenous biological clocks, orchestrated by the suprachiasmatic nucleus, time the
circadian rhythms that synchronize physiological and behavioural functions in humans. The …

Parkinson's disease prevalence is rapidly increasing in an aging global population. With this
increase comes exponentially rising social and economic costs, emphasizing the immediate …

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly
regarded as being in the early stages of a progressive neurodegenerative disease involving …

The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive
impairment (MCI),(2) delirium-onset, and (3) psychiatric-onset presentations. The purpose of …

Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …